Context Therapeutics, Inc. CNTX 深 滬
等待開盤 06-03 09:30:00 美东时间
2.485
-0.305
-10.93%
華盛通- 最 高2.80
- 今 開2.77
- 成交量 42.58万股
- 最 低 2.465
- 昨 收 2.79
- 總市值 2.28亿
- 52周最高 3.62
- 市盈率 靜 --
- 換手率 0.46%
- 52周最低 0.56
- 委 比 7.07%
- 總股本 9187.92万
- 歷史最高 10.87
- 量 比 0.59
- 振 幅 12.01%
- 歷史最低 0.47
- 每 手 1
- 風險率 0.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1
Phase 1 initiation for CT-202 trial expected in third quarter of 2026
05-18 18:49
Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 80 percent decrease over losses of $(0.05) per share from
05-07 04:54
Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer
Context Therapeutics Inc. ("Context" or the "Company") (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced that the U.S.
04-02 19:34
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7
Piper Sandler analyst Biren Amin maintains Context Therapeutics (NASDAQ:CNTX) with a Overweight and raises the price target from $4 to $7.
03-24 20:59
Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.10) by 34.62 percent.
03-24 04:20
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7
Jones Trading analyst Soumit Roy initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price Target of $7.
2025-12-22 20:25
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5
HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $5.
2025-11-06 19:52
